Pharmacokinetics and biodistribution of genetically-engineered antibodies

D. Colcher, G. Pavlinkova, G. Beresford, B. J M Booth, A. Choudhury, Surinder Kumar Batra

Research output: Contribution to journalReview article

155 Citations (Scopus)

Abstract

Monoclonal antibodies (MAbs), because of their inherent specificity, are ideal targeting agents. They can be used to deliver radionuclides, toxins or cytotoxic drugs to a specific tissue or malignant cell populations. Intact immunoglobulin (IgG) molecules have several practical limitations of their pharmacology; their relatively large size of approximately 150,000 daltons leads to a slow clearance from the blood pool and the body resulting in significant exposure to normal organs with limited quantities delivered to tumors. The IgG molecule shows a relatively poor diffusion from the vasculature into and through the tumor. Attempts to modify the pharmacology of the Ig molecule have classically involved the use of proteases to generate F(ab')2 and Fab' fragments with molec-binding affinity similar to that of a monovalent Fab' fragment; this however, represents a relative decrease in binding affinity when compared to intact antibodies. The scFv with its faster clearance and lower affinity results in a lower percent-injected dose localizing in tumors when compared to the divalent IgG molecule. This may be adequate for imaging but probably not for therapy. The valency of the MAb fragment is critical for the functional affinity of an antibody to a cell surface or a polymeric antigen. In attempts to generate multivalent forms of scFv molecules, noncovalently linked scFv dimeric and trimeric molecules, disulfide linked dimeric scFvs, as well as covalently linked chimetic scFvs have been studied. These multivalent scFvs generally have a higher functional affinity than the monovalent form resulting in better in vivo targeting. Another way to alter the pharmacology of the scFvs is to modify its net charge. Charge-modified scFvs with desired isoelectric points (pI), have been prepared by inserting negatively charged amino acids on the template of the variable region genes. This can help to overcome undesirable elevations in renal uptake seen with most antibody fragments. In conclusion, genetic manipulations of the immunoglobulin molecules are effective means of altering stability, functional affinity, pharmacokinetics, and biodistribution of the antibodies required for the generation of the 'magic bullet'.

Original languageEnglish (US)
Pages (from-to)225-241
Number of pages17
JournalQuarterly Journal of Nuclear Medicine
Volume42
Issue number4
StatePublished - Dec 1 1998

Fingerprint

Immunoglobulin Fab Fragments
Pharmacokinetics
Immunoglobulin G
Pharmacology
Antibodies
Immunoglobulins
Neoplasms
Immunoglobulin Fragments
Magic
Antibody Affinity
Isoelectric Point
Radioisotopes
Disulfides
Peptide Hydrolases
Monoclonal Antibodies
Kidney
Antigens
Amino Acids
Pharmaceutical Preparations
Population

Keywords

  • Antibodies
  • Antibody engineering
  • Monoclonal
  • Single chain antibody fragments

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Colcher, D., Pavlinkova, G., Beresford, G., Booth, B. J. M., Choudhury, A., & Batra, S. K. (1998). Pharmacokinetics and biodistribution of genetically-engineered antibodies. Quarterly Journal of Nuclear Medicine, 42(4), 225-241.

Pharmacokinetics and biodistribution of genetically-engineered antibodies. / Colcher, D.; Pavlinkova, G.; Beresford, G.; Booth, B. J M; Choudhury, A.; Batra, Surinder Kumar.

In: Quarterly Journal of Nuclear Medicine, Vol. 42, No. 4, 01.12.1998, p. 225-241.

Research output: Contribution to journalReview article

Colcher, D, Pavlinkova, G, Beresford, G, Booth, BJM, Choudhury, A & Batra, SK 1998, 'Pharmacokinetics and biodistribution of genetically-engineered antibodies', Quarterly Journal of Nuclear Medicine, vol. 42, no. 4, pp. 225-241.
Colcher D, Pavlinkova G, Beresford G, Booth BJM, Choudhury A, Batra SK. Pharmacokinetics and biodistribution of genetically-engineered antibodies. Quarterly Journal of Nuclear Medicine. 1998 Dec 1;42(4):225-241.
Colcher, D. ; Pavlinkova, G. ; Beresford, G. ; Booth, B. J M ; Choudhury, A. ; Batra, Surinder Kumar. / Pharmacokinetics and biodistribution of genetically-engineered antibodies. In: Quarterly Journal of Nuclear Medicine. 1998 ; Vol. 42, No. 4. pp. 225-241.
@article{64560ce23d3949818a21a75384767403,
title = "Pharmacokinetics and biodistribution of genetically-engineered antibodies",
abstract = "Monoclonal antibodies (MAbs), because of their inherent specificity, are ideal targeting agents. They can be used to deliver radionuclides, toxins or cytotoxic drugs to a specific tissue or malignant cell populations. Intact immunoglobulin (IgG) molecules have several practical limitations of their pharmacology; their relatively large size of approximately 150,000 daltons leads to a slow clearance from the blood pool and the body resulting in significant exposure to normal organs with limited quantities delivered to tumors. The IgG molecule shows a relatively poor diffusion from the vasculature into and through the tumor. Attempts to modify the pharmacology of the Ig molecule have classically involved the use of proteases to generate F(ab')2 and Fab' fragments with molec-binding affinity similar to that of a monovalent Fab' fragment; this however, represents a relative decrease in binding affinity when compared to intact antibodies. The scFv with its faster clearance and lower affinity results in a lower percent-injected dose localizing in tumors when compared to the divalent IgG molecule. This may be adequate for imaging but probably not for therapy. The valency of the MAb fragment is critical for the functional affinity of an antibody to a cell surface or a polymeric antigen. In attempts to generate multivalent forms of scFv molecules, noncovalently linked scFv dimeric and trimeric molecules, disulfide linked dimeric scFvs, as well as covalently linked chimetic scFvs have been studied. These multivalent scFvs generally have a higher functional affinity than the monovalent form resulting in better in vivo targeting. Another way to alter the pharmacology of the scFvs is to modify its net charge. Charge-modified scFvs with desired isoelectric points (pI), have been prepared by inserting negatively charged amino acids on the template of the variable region genes. This can help to overcome undesirable elevations in renal uptake seen with most antibody fragments. In conclusion, genetic manipulations of the immunoglobulin molecules are effective means of altering stability, functional affinity, pharmacokinetics, and biodistribution of the antibodies required for the generation of the 'magic bullet'.",
keywords = "Antibodies, Antibody engineering, Monoclonal, Single chain antibody fragments",
author = "D. Colcher and G. Pavlinkova and G. Beresford and Booth, {B. J M} and A. Choudhury and Batra, {Surinder Kumar}",
year = "1998",
month = "12",
day = "1",
language = "English (US)",
volume = "42",
pages = "225--241",
journal = "Quarterly Journal of Nuclear Medicine and Molecular Imaging",
issn = "1824-4785",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "4",

}

TY - JOUR

T1 - Pharmacokinetics and biodistribution of genetically-engineered antibodies

AU - Colcher, D.

AU - Pavlinkova, G.

AU - Beresford, G.

AU - Booth, B. J M

AU - Choudhury, A.

AU - Batra, Surinder Kumar

PY - 1998/12/1

Y1 - 1998/12/1

N2 - Monoclonal antibodies (MAbs), because of their inherent specificity, are ideal targeting agents. They can be used to deliver radionuclides, toxins or cytotoxic drugs to a specific tissue or malignant cell populations. Intact immunoglobulin (IgG) molecules have several practical limitations of their pharmacology; their relatively large size of approximately 150,000 daltons leads to a slow clearance from the blood pool and the body resulting in significant exposure to normal organs with limited quantities delivered to tumors. The IgG molecule shows a relatively poor diffusion from the vasculature into and through the tumor. Attempts to modify the pharmacology of the Ig molecule have classically involved the use of proteases to generate F(ab')2 and Fab' fragments with molec-binding affinity similar to that of a monovalent Fab' fragment; this however, represents a relative decrease in binding affinity when compared to intact antibodies. The scFv with its faster clearance and lower affinity results in a lower percent-injected dose localizing in tumors when compared to the divalent IgG molecule. This may be adequate for imaging but probably not for therapy. The valency of the MAb fragment is critical for the functional affinity of an antibody to a cell surface or a polymeric antigen. In attempts to generate multivalent forms of scFv molecules, noncovalently linked scFv dimeric and trimeric molecules, disulfide linked dimeric scFvs, as well as covalently linked chimetic scFvs have been studied. These multivalent scFvs generally have a higher functional affinity than the monovalent form resulting in better in vivo targeting. Another way to alter the pharmacology of the scFvs is to modify its net charge. Charge-modified scFvs with desired isoelectric points (pI), have been prepared by inserting negatively charged amino acids on the template of the variable region genes. This can help to overcome undesirable elevations in renal uptake seen with most antibody fragments. In conclusion, genetic manipulations of the immunoglobulin molecules are effective means of altering stability, functional affinity, pharmacokinetics, and biodistribution of the antibodies required for the generation of the 'magic bullet'.

AB - Monoclonal antibodies (MAbs), because of their inherent specificity, are ideal targeting agents. They can be used to deliver radionuclides, toxins or cytotoxic drugs to a specific tissue or malignant cell populations. Intact immunoglobulin (IgG) molecules have several practical limitations of their pharmacology; their relatively large size of approximately 150,000 daltons leads to a slow clearance from the blood pool and the body resulting in significant exposure to normal organs with limited quantities delivered to tumors. The IgG molecule shows a relatively poor diffusion from the vasculature into and through the tumor. Attempts to modify the pharmacology of the Ig molecule have classically involved the use of proteases to generate F(ab')2 and Fab' fragments with molec-binding affinity similar to that of a monovalent Fab' fragment; this however, represents a relative decrease in binding affinity when compared to intact antibodies. The scFv with its faster clearance and lower affinity results in a lower percent-injected dose localizing in tumors when compared to the divalent IgG molecule. This may be adequate for imaging but probably not for therapy. The valency of the MAb fragment is critical for the functional affinity of an antibody to a cell surface or a polymeric antigen. In attempts to generate multivalent forms of scFv molecules, noncovalently linked scFv dimeric and trimeric molecules, disulfide linked dimeric scFvs, as well as covalently linked chimetic scFvs have been studied. These multivalent scFvs generally have a higher functional affinity than the monovalent form resulting in better in vivo targeting. Another way to alter the pharmacology of the scFvs is to modify its net charge. Charge-modified scFvs with desired isoelectric points (pI), have been prepared by inserting negatively charged amino acids on the template of the variable region genes. This can help to overcome undesirable elevations in renal uptake seen with most antibody fragments. In conclusion, genetic manipulations of the immunoglobulin molecules are effective means of altering stability, functional affinity, pharmacokinetics, and biodistribution of the antibodies required for the generation of the 'magic bullet'.

KW - Antibodies

KW - Antibody engineering

KW - Monoclonal

KW - Single chain antibody fragments

UR - http://www.scopus.com/inward/record.url?scp=0032422140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032422140&partnerID=8YFLogxK

M3 - Review article

C2 - 9973838

AN - SCOPUS:0032422140

VL - 42

SP - 225

EP - 241

JO - Quarterly Journal of Nuclear Medicine and Molecular Imaging

JF - Quarterly Journal of Nuclear Medicine and Molecular Imaging

SN - 1824-4785

IS - 4

ER -